TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01602913

Intervention type: DRUG
Intervention: Pravastatin alone
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.

Intervention type: DRUG
Intervention: Pravastatin alone
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
Study: NCT01059825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Study: NCT01602913

Intervention type: DRUG
Intervention: Paroxetine alone
Description: Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression

Intervention type: DRUG
Intervention: Paroxetine alone
Description: Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression

Intervention type: DRUG
Intervention: Pravastatin and paroxetine combined
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression

Intervention type: DRUG
Intervention: Pravastatin and paroxetine combined
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
Study: NCT00145587

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS
Description: Stem cell selection device

Intervention type: DRUG
Group type: OTHER
Intervention: Systemic chemotherapy and antibodies
Description: Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis.
Study: NCT04359017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
Study: NCT01534546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin capecitabine
Description: capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin S-1
Description: S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin S-1
Description: S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
Study: NCT01337141

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 7 face-to-face visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecare system
Description: 5 telematic visits and 2 face-to-face visits.
Study: NCT05040828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.
Description: Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.
Description: 10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Study: NCT01059825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Description: Tablet, 1 mg, once daily for 84 days
Study: NCT06606340

Intervention type: DRUG
Intervention: Eteplirsen
Description: No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.

Intervention type: DRUG
Intervention: Golodirsen
Description: No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.

Intervention type: DRUG
Intervention: Casimersen
Description: No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
Study: NCT01059825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
Study: NCT02455518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/acetaminophen
Study: NCT05040828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No oral drug therapy throughout the pollen period
Description: Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Study: NCT02403375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Insight Pump System
Description: Continuous subcutaneous insulin infusion pump
Study: NCT02455518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine/acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen/acetaminophen
Study: NCT02309138

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gestational diabetes screening with fasting 3 hour 100 gm
Description: Participants receive fasting 3 hour 100 gm oral glucose tolerance test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gestational diabetes screening with fasting 2 hour 75g
Description: Participants receive fasting 2 hour 75 gm oral glucose tolerance test
Study: NCT01982448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01562561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 2 mg at each main meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
Study: NCT03145389

Intervention type: PROCEDURE
Intervention: Epidural catheter placement
Description: After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
Study: NCT00086281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (X)
Description: Xyrem (Sodium Oxybate) Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (X)
Description: Xyrem (Sodium Oxybate) Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem (Z)
Description: Zolpidem 10 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil (M)
Description: Modafinil Oral Tablets
Study: NCT01437410

Intervention type: PROCEDURE
Intervention: EUS-FNA
Description: tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
Study: NCT02987218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
Study: NCT02094534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Capsules
Description: API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fish oil capsules, identical in appearance to the experimental intervention.
Study: NCT03100188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified PD prescription
Description: For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
Study: NCT03926702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiopharmaceuticals
Description: All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
Study: NCT00570388

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prometa Treatment Program
Description: Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometa Treatment Program
Description: Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.
Study: NCT02379000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpupillary thermotherapy
Description: We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpupillary thermotherapy
Description: We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
Study: NCT01005849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protecflor
Description: 1 Capsule to be taken once a day during the entire study period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Capsule to be taken once a day during the entire study period
Study: NCT03559205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MSK-Tracker
Description: The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring.
Study: NCT01059825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Description: Tablet, 25 mg, once daily for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Tablet, 100 mg, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days
Study: NCT00248118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: During treatment phase, participants will take 300 mg bupropion or placebo daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: During treatment phase, participants will take 300 mg bupropion or placebo daily.
Study: NCT01059825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days
Study: NCT02987907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: use dexamethasone 10mg (2ml) I.A. during TACE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: use normal saline 2ml I.A. during TACE
Study: NCT01059825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Study: NCT03217877

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: routine stress testing
Description: In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No Routine stress testing
Description: In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
Study: NCT03786302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAMP bioglass
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Study: NCT03117790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
Study: NCT00497549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: side-to-side stapled
Description: 5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand sewn
Description: A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
Study: NCT02968160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg + Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg + Rosuvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 40mg, 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Study: NCT03539289

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MUFA Diet
Description: Control of patient MUFA Diet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SFA Diet
Description: Control of patient SFA Diet
Study: NCT01575015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Description: Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard intraoperative support
Description: Patients allocated to standard intraoperative support will receive usual care (no CRRT).
Study: NCT03524755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise